Pfizer Inc. (PFE) News
Filter PFE News Items
PFE News Results
|Loading, please wait...|
PFE News Highlights
- PFE's 30 day story count now stands at 77.
- Over the past 29 days, the trend for PFE's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
- DRUG, AGE and MRNA are the most mentioned tickers in articles about PFE.
Latest PFE News From Around the Web
Below are the latest news stories about Pfizer Inc that investors may wish to consider to help them evaluate PFE as an investment opportunity.
Here are four pharma stocks that looks attractive for the long-term.
NVAX stock is one of the major players in the vaccine market, which is one that is expected to grow substantially over the next few years.
The European Union's health regulator on Thursday backed giving a booster shot of Pfizer and BioNTech's COVID-19 vaccine to adolescents aged 12 and over, as well as the expanded use of Moderna's shot in children ages six to 11. The recommendations by the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use will be followed by final decisions by the European Commission. The moves come after several EU countries already started to offer booster doses of the Pfizer/BioNTech vaccine to teens.
Buying and holding quality growth stocks can be a surefire way to significantly increase your portfolio's value over the years. Two growth stocks that show lots of promise and are down more than 60% from their 52-week highs are BioNTech SE (NASDAQ: BNTX) and Matterport (NASDAQ: MTTR). Healthcare company BioNTech finished last week at less than $157 per share -- down more than 66% from the $464 it peaked at last Aug. 10, which was just after the release of its second-quarter results.
Moderna executives have revealed data showing that the protection afforded by its booster shot will begin to wane after about nine months, regardless of what vaccine a patient had used in the primary series.
In this article, we discuss the 10 best dividend stocks to buy according to Kahn Brothers. You can skip our detailed analysis of the hedge fund’s investment philosophy, and go directly to read 5 Best Dividend Stocks to Buy According to Kahn Brothers. Kahn Brothers Group, an investment management firm, was founded by Irving Kahn, […]
Pfizer, Nike, Walmart, and Broadcom are among the companies that have built up a war chest of cash and are considered prime buyback candidates.
Extending the interval between the first two doses of the most widely used COVID-19 vaccines in the country to eight weeks for young men can reduce the rare risk of heart inflammation, U.S. health officials said. The side effect, which has been linked to both Pfizer and Moderna's COVID-19 vaccines, is higher in 12- to 39-year-old men, and therefore the eight-week interval could be optimal for some people aged 12 years and older, the U.S. Centers for Disease Control and Prevention said https://bit.ly/3IfIj9H on Tuesday. The recommended interval between the first two shots will remain three weeks for Pfizer's vaccine and four weeks for Moderna's vaccine in other population groups, the CDC said.
Sanofi and GlaxoSmithKline plan to submit their long-awaited Covid-19 vaccine for regulatory approval. Data suggest it's a contender against Pfizer and Moderna boosters.
In this clip from "The Health & Fitness Show" on Motley Fool Live, recorded on Feb. 11, Motley Fool contributors Brian Orelli, Meilin Quinn, and Sanmeet Deo talk about Pfizer's (NYSE: PFE) potential to hit $100 billion in total revenue and discuss how sustainable its stream of revenue is from its COVID-19 vaccine and treatment. Brian Orelli: So Pfizer doubled its revenue year-over-year, which was maybe not so surprising since it had sales of its vaccine for COVID-19 that basically that entire doubling was the COVID-19 vaccine.